Supplementation with NAD⁺ and Its Precursors to Prevent Cognitive Decline across Disease Contexts

Simple item page
dc.contributor.authorCampbell, J.M.
dc.date.issued2022
dc.description.abstractThe preservation of cognitive ability by increasing nicotinamide adenine dinucleotide (NAD+) levels through supplementation with NAD+ precursors has been identified as a promising treatment strategy for a number of conditions; principally, age-related cognitive decline (including Alzheimer’s disease and vascular dementia), but also diabetes, stroke, and traumatic brain injury. Candidate factors have included NAD+ itself, its reduced form NADH, nicotinamide (NAM), nicotinamide mononucleotide (NMN), nicotinamide riboside (NR), and niacin (or nicotinic acid). This review summarises the research findings for each source of cognitive impairment for which NAD+ precursor supplementation has been investigated as a therapy. The findings are mostly positive but have been made primarily in animal models, with some reports of null or adverse effects. Given the increasing popularity and availability of these factors as nutritional supplements, further properly controlled clinical research is needed to provide definitive answers regarding this strategy’s likely impact on human cognitive health when used to address different sources of impairment.
dc.description.statementofresponsibilityJared M. Campbell
dc.identifier.citationNutrients, 2022; 14(15):3231-1-3231-11
dc.identifier.doi10.3390/nu14153231
dc.identifier.issn2072-6643
dc.identifier.issn2072-6643
dc.identifier.orcidCampbell, J.M. [0000-0003-0163-4251]
dc.identifier.urihttps://hdl.handle.net/2440/136171
dc.language.isoen
dc.publisherMDPI AG
dc.relation.granthttp://purl.org/au-research/grants/arc/DP210102960
dc.rights© 2022 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).
dc.source.urihttps://doi.org/10.3390/nu14153231
dc.subjectcognitive health; cognitive decline; neuroprotection; NAD; NADH; nicotinamide riboside; nicotinamide mono nucleotide; nicotinamide; dementia; stroke; diabetes; traumatic brain injury
dc.titleSupplementation with NAD⁺ and Its Precursors to Prevent Cognitive Decline across Disease Contexts
dc.typeJournal article
pubs.publication-statusPublished

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
hdl_136171.pdf
Size:
396.75 KB
Format:
Adobe Portable Document Format
Description:
Published version
Download

Collections

Medicine publications